Theriva Presents Next-Gen Oncolytic Adenovirus VCN-12 at ESGCT
Preclinical biodistribution and toxicity results from intracranial dosing of VCN-01 in a Syrian hamster model support feasibility for brain...
Verrica Presents New VP-315 Data for Basal Cell Carcinoma
No efficacy or safety data accompanied the announcement. Verrica said the SITC presentation will report an exploratory analysis from...
Neurona Expands NRTX-1001 Cell Therapy Trial for Epilepsy
In updated Phase 1/2 data for unilateral mesial temporal lobe epilepsy (MTLE), a single low dose of NRTX-1001 produced...
Innovative Heartworm Breath Test Completes First Phase Study
Global Innovative Platforms completed a 12‑month, >100‑sample feasibility effort evaluating breath-based detection of canine heartworm infection, to enable point‑of‑care...
Atea’s New HCV Combo Aims for Best-in-Class Treatment
Atea reported 98% SVR12 (210/215) in the per‑protocol, treatment‑adherent cohort and 95% SVR12 (245/259) in the per‑protocol, regardless‑of‑adherence cohort...
Pembrolizumab & CNV-NT Combo Study Results in Solid Tumors
Biomed Valley Discoveries reported a 25% confirmed objective response rate (4 of 16 patients) with a median response duration...
Spur Therapeutics Presents Updated Gaucher Gene Therapy Data
Four adults with type 1 Gaucher disease who received a single low dose of avigbagene parvec (FLT201; 4.5e11 vg/kg)...
Arvinas’ PROTAC Degrader Shows Positive Phase 1 Parkinson’s Data
ARV-102 delivered dose-dependent exposure in plasma and CSF, was well tolerated with no serious adverse events or discontinuations, and...
FDA Approves First PNS Device for Chronic Craniofacial Pain
Topline data: In a prospective, multi-center IDE randomized controlled trial for chronic craniofacial pain, 69% of patients on active...
Quantum MS Drug Breakthrough Moves Closer to Phase 2 Trial
Quantum BioPharma has received final 90-day oral toxicity and toxicokinetic reports for Lucid-21-302 (Lucid-MS), positioning the program to support...